MedPath

Macrilen

These highlights do not include all the information needed to use MACRILEN safely and effectively. See full prescribing information for MACRILEN.MACRILEN (macimorelin) for oral solution Initial U.S. Approval: 2017

Approved
Approval ID

6034c9b8-5a36-4961-a5dd-11ebf7bdab78

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 30, 2021

Manufacturers
FDA

Novo Nordisk

DUNS: 622920320

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Macimorelin acetate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0169-1401
Application NumberNDA205598
Product Classification
M
Marketing Category
C73594
G
Generic Name
Macimorelin acetate
Product Specifications
Route of AdministrationORAL
Effective DateNovember 27, 2023
FDA Product Classification

INGREDIENTS (6)

Silicon DioxideInactive
Code: ETJ7Z6XBU4
Classification: IACT
Sodium Stearyl FumarateInactive
Code: 7CV7WJK4UI
Classification: IACT
Saccharin SodiumInactive
Code: SB8ZUX40TY
Classification: IACT
CROSPOVIDONE, UNSPECIFIEDInactive
Code: 2S7830E561
Classification: IACT
MACIMORELINActive
Quantity: 60 mg in 1 mg
Code: 8680B21W73
Classification: ACTIB
Lactose MonohydrateInactive
Code: EWQ57Q8I5X
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Macrilen - FDA Drug Approval Details